{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:58:29Z","timestamp":1785351509824,"version":"3.55.0"},"reference-count":126,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Breast and ovarian cancers are major public health challenges, with rising breast cancer incidence and persistently high ovarian cancer mortality. Approximately 10% of breast cancers and up to 25% of ovarian cancers are attributable to germline pathogenic variants (also called mutations) in cancer susceptibility genes, most notably\n                    <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                    \/\n                    <jats:italic toggle=\"yes\">2,<\/jats:italic>\n                    but several other genes also contribute to risk of ovarian and breast cancers. Identification of pathogenic variants enables targeted prevention and early detection strategies, including enhanced surveillance and risk-reducing surgery, which can significantly decrease cancer incidence, morbidity, and mortality. We seek to review the specific risks of breast and ovarian cancer\u2013associated genes and management strategies. Advances in sequencing technology, reduced sequencing costs, and legislative protections against genetic discrimination have expanded access to genetic testing, and clinical guidelines have broadened the pool of individuals recommended for testing. Despite these advances, most individuals with hereditary cancer syndromes remain undiagnosed, limiting the reach of precision cancer prevention. Underutilization of genetic testing is particularly pronounced among underserved populations, perpetuating disparities in health outcomes. Emerging health care delivery models have improved uptake and reduced barriers and can be considered for integration into obstetrics and gynecology practices. Ongoing research into the fallopian tube origin of high-grade serous ovarian cancer has prompted research that may expand risk-reducing surgical options. Collectively, these innovations mark a transformative era in hereditary cancer care, emphasizing access, multidisciplinary integration, and the urgent need for novel delivery models to ensure that the benefits of genetic testing reach all individuals at risk.\n                  <\/jats:p>","DOI":"10.1097\/aog.0000000000006304","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:00:51Z","timestamp":1778187651000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary Breast and Ovarian Cancer"],"prefix":"10.1097","author":[{"given":"Ying L.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varshini","family":"Gali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"K. Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","article-title":"Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center","volume":"36","author":"Chapman-Davis","year":"2021","journal-title":"J Gen Int Med"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12609-020-00364-1","article-title":"Disparities in genetic testing and care among Black women with hereditary breast cancer","volume":"12","author":"Reid","year":"2020","journal-title":"Curr Breast Cancer Rep"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.30621","article-title":"Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors","volume":"123","author":"Cragun","year":"2017","journal-title":"Cancer"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","article-title":"Racial differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer","volume":"293","author":"Armstrong","year":"2005","journal-title":"JAMA"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2019.01.024","article-title":"Disparities in gynecologic cancer genetics evaluation","volume":"153","author":"Hinchcliff","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/oncolo\/oyac132","article-title":"The role of race and insurance status in access to genetic counseling and testing among high-risk breast cancer patients","volume":"27","author":"Choi","year":"2022","journal-title":"Oncologist"},{"key":"R14-20260729","first-page":"1","article-title":"Genetic testing for all: overcoming disparities in ovarian cancer genetic testing","volume":"42","author":"Frey","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ng1294-399","article-title":"Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families","volume":"8","author":"Friedman","year":"1994","journal-title":"Nat Genet"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet Med"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ogc.2021.11.005","article-title":"Hereditary breast and ovarian cancer: an updated primer for OB\/GYNs","volume":"49","author":"Bellcross","year":"2022","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1056\/NEJMp0803964","article-title":"Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008","volume":"358","author":"Hudson","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/302714","article-title":"Laws restricting health insurers' use of genetic information: impact on genetic discrimination","volume":"66","author":"Hall","year":"2000","journal-title":"Am J Hum Genet"},{"key":"R22-20260729","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"R23-20260729","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"R24-20260729","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of variant reclassification following hereditary cancer genetic testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"key":"R25-20260729","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res"},{"key":"R26-20260729","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","article-title":"The Fanconi anemia pathway in cancer","volume":"3","author":"Niraj","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"R27-20260729","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"key":"R28-20260729","doi-asserted-by":"crossref","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R30-20260729","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/ajmg.a.40374","article-title":"Health supervision for people with Bloom syndrome","volume":"176","author":"Cunniff","year":"2018","journal-title":"Am J Med Genet A"},{"key":"R31-20260729","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/cancers11101548","article-title":"Inherited variants in BLM and the risk and clinical characteristics of breast cancer","volume":"11","author":"Klu\u017aniak","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R33-20260729","doi-asserted-by":"crossref","first-page":"531790","DOI":"10.3389\/fonc.2020.531790","article-title":"Pathology of hereditary breast and ovarian cancer","volume":"10","author":"Hodgson","year":"2020","journal-title":"Front Oncol"},{"key":"R34-20260729","doi-asserted-by":"crossref","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Mavaddat","year":"2022","journal-title":"JAMA Oncol"},{"key":"R35-20260729","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"R36-20260729","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jnci\/djab036","article-title":"Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study","volume":"113","author":"de Jonge","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R37-20260729","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2025.08.030","article-title":"Risk of melanoma among people with BRCA1 and BRCA2 pathogenic variants: a systematic review and meta-analysis","volume":"201","author":"Frontera","year":"2025","journal-title":"Gynecol Oncol"},{"key":"R38-20260729","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa2211807","article-title":"Helicobacter pylori, homologous-recombination genes, and gastric cancer","volume":"388","author":"Usui","year":"2023","journal-title":"N Engl J Med"},{"key":"R39-20260729","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol"},{"key":"R40-20260729","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cncr.26424","article-title":"Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis","volume":"118","author":"Lowry","year":"2012","journal-title":"Cancer"},{"key":"R41-20260729","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"R42-20260729","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/jamaoncol.2025.2203","article-title":"Defining lifetime risk thresholds for breast cancer surgical prevention","volume":"11","author":"Wei","year":"2025","journal-title":"JAMA Oncol"},{"key":"R43-20260729","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R44-20260729","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"R45-20260729","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol"},{"key":"R46-20260729","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers16010103","article-title":"Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in BRCA1\/2 carriers","volume":"16","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R47-20260729","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"R48-20260729","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R49-20260729","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.24.00176","article-title":"Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"R50-20260729","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"R51-20260729","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2019.5780","article-title":"Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"R52-20260729","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"R53-20260729","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet Med"},{"key":"R54-20260729","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R55-20260729","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"key":"R56-20260729","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res"},{"key":"R57-20260729","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"key":"R58-20260729","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2024.10852","article-title":"Germline CDH1 variants and lifetime cancer risk","volume":"332","author":"Ryan","year":"2024","journal-title":"JAMA"},{"key":"R59-20260729","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PAP.0000000000000177","article-title":"Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2","volume":"25","author":"Hoang","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"R60-20260729","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/diagnostics11010084","article-title":"MUTYH as an emerging predictive biomarker in ovarian cancer","volume":"11","author":"Hutchcraft","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R61-20260729","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2025.03.029","article-title":"MUTYH: possibly another important gene in ovarian cancer?","volume":"196","author":"Haghighat","year":"2025","journal-title":"Gynecol Oncol"},{"key":"R63-20260729","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10689-021-00285-7","article-title":"Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer","volume":"21","author":"Thompson","year":"2022","journal-title":"Fam Cancer"},{"key":"R64-20260729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/13892029113146660012","article-title":"NBN gene polymorphisms and cancer susceptibility: a systemic review","volume":"14","author":"Berardinelli","year":"2013","journal-title":"Curr Genomics"},{"key":"R65-20260729","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.3390\/ijms22115832","article-title":"Detecting variants in the NBN gene while testing for hereditary breast cancer: what to do next?","volume":"22","author":"Zuntini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R66-20260729","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bjc.2015.78","article-title":"Age-specific risk of breast cancer in women with neurofibromatosis type 1","volume":"112","author":"Seminog","year":"2015","journal-title":"Br J Cancer"},{"key":"R67-20260729","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/ajmg.a.35550","article-title":"Increased risk of breast cancer in women with NF1","volume":"158A","author":"Madanikia","year":"2012","journal-title":"Am J Med Genet A"},{"key":"R68-20260729","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.gde.2021.06.010","article-title":"RAD51 paralog function in replicative DNA damage and tolerance","volume":"71","author":"Rein","year":"2021","journal-title":"Curr Opin Genet Dev"},{"key":"R69-20260729","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41523-021-00339-0","article-title":"Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination","volume":"7","author":"Setton","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"R70-20260729","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms18091886","article-title":"The role of PALB2 in the DNA damage response and cancer predisposition","volume":"18","author":"Nepomuceno","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R71-20260729","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2023.07.017","article-title":"Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: a systematic review and meta-analysis","volume":"177","author":"Narayan","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R72-20260729","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R73-20260729","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1172\/JCI121277","article-title":"PTEN-opathies: from biological insights to evidence-based precision medicine","volume":"129","author":"Yehia","year":"2019","journal-title":"J Clin Invest"},{"key":"R74-20260729","article-title":"GeneReviews [Internet]: Li-Fraumeni syndrome","author":"Schneider"},{"key":"R75-20260729","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10689-017-0037-3","article-title":"An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review","volume":"17","author":"Daniell","year":"2018","journal-title":"Fam Cancer"},{"key":"R76-20260729","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/OP.21.00382","article-title":"Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes","volume":"18","author":"Liu","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"R77-20260729","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R78-20260729","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jmedgenet-2013-102015","article-title":"Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants","volume":"51","author":"Jervis","year":"2014","journal-title":"J Med Genet"},{"key":"R79-20260729","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R80-20260729","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","article-title":"Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis","volume":"53","author":"Manchanda","year":"2016","journal-title":"J Med Genet"},{"key":"R81-20260729","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"R82-20260729","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"R83-20260729","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"R84-20260729","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ejso.2022.02.019","article-title":"Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: a systematic review and meta-analysis","volume":"48","author":"Wang","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"R85-20260729","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2005.05.002","article-title":"Clinical practice committee statement on prophylactic salpingo-oophorectomy","volume":"98","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R86-20260729","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R87-20260729","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ajog.2006.03.006","article-title":"Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy","volume":"194","author":"Lamb","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R88-20260729","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol","volume":"21","author":"Powell","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R89-20260729","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","article-title":"Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up","volume":"90","author":"Olivier","year":"2004","journal-title":"Br J Cancer"},{"key":"R90-20260729","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R91-20260729","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","article-title":"Microscopic and early-stage ovarian cancers in BRCA1\/2 mutation carriers: building a model for early BRCA-associated tumorigenesis","volume":"4","author":"Yates","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"R92-20260729","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur J Cancer"},{"key":"R93-20260729","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R94-20260729","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jmig.2017.04.017","article-title":"Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience","volume":"24","author":"Bogani","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"R95-20260729","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11845-017-1717-6","article-title":"Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes","volume":"187","author":"Thompson","year":"2018","journal-title":"Ir J Med Sci"},{"key":"R96-20260729","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J Clin Oncol"},{"key":"R97-20260729","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.3390\/diagnostics14222577","article-title":"Serous tubal intraepithelial carcinoma (STIC): a review of the literature on the incidence at the time of prophylactic surgery","volume":"14","author":"Luvero","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R98-20260729","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2020.02.006","article-title":"Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience","volume":"157","author":"Rush","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R99-20260729","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers","volume":"124","author":"Domchek","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R100-20260729","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.21.02016","article-title":"Risk of peritoneal carcinomatosis after risk-reducing salpingo-Oophorectomy: a systematic review and individual patient data meta-analysis","volume":"40","author":"Steenbeek","year":"2022","journal-title":"J Clin Oncol"},{"key":"R101-20260729","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","article-title":"Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study","volume":"113","author":"Parker","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R102-20260729","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R103-20260729","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"key":"R104-20260729","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1212\/01.wnl.0000280573.30975.6a","article-title":"Increased risk of Parkinsonism in women who underwent oophorectomy before menopause","volume":"70","author":"Rocca","year":"2008","journal-title":"Neurology"},{"key":"R105-20260729","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/GME.0000000000002201","article-title":"Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1\/2 mutation carriers","volume":"30","author":"DiSilvestro","year":"2023","journal-title":"Menopause"},{"key":"R106-20260729","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"R107-20260729","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R108-20260729","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2015.12.003","article-title":"Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis","volume":"55","author":"Yoon","year":"2016","journal-title":"Eur J Cancer"},{"key":"R109-20260729","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/AOG.0000000000003164","article-title":"Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. ACOG Committee Opinion No. 774. American College of Obstetricians & Gynecologists","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R110-20260729","doi-asserted-by":"crossref","first-page":"e2147343","DOI":"10.1001\/jamanetworkopen.2021.47343","article-title":"Outcomes from opportunistic salpingectomy for ovarian cancer prevention","volume":"5","author":"Hanley","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R111-20260729","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/bjs.11419","article-title":"Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy","volume":"107","author":"Tomasch","year":"2020","journal-title":"Br J Surg"},{"key":"R112-20260729","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1245\/s10434-012-2257-y","article-title":"Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers","volume":"19","author":"Drohan","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R113-20260729","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/AOG.0000000000002916","article-title":"Hereditary cancer risk assessment and genetic testing in the community-practice setting","volume":"132","author":"DeFrancesco","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R114-20260729","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/AOG.0000000000004596","article-title":"Hereditary cancer risk using a genetic chatbot before routine care visits","volume":"138","author":"Nazareth","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R115-20260729","doi-asserted-by":"crossref","first-page":"301.e1","DOI":"10.1016\/j.ajog.2025.03.026","article-title":"Digital tool for genetic cancer risk assessment in a historically underserved population: a randomized controlled trial","volume":"233","author":"Webster","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R116-20260729","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2024.03.004","article-title":"Personalized survivorship care: routine breast cancer risk assessment in the gynecologic oncology clinic","volume":"183","author":"Ahsan","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R117-20260729","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2021.05.011","article-title":"Achieving universal genetic assessment for women with ovarian cancer: are we there yet? A systematic review and meta-analysis","volume":"162","author":"Lin","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R118-20260729","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ajog.2025.04.044","article-title":"Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis","volume":"233","author":"Kalra","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R119-20260729","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/GIM.0b013e31821882b7","article-title":"Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce","volume":"13","author":"Blazer","year":"2011","journal-title":"Genet Med"},{"key":"R120-20260729","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13187-012-0313-8","article-title":"Impact of web-based case conferencing on cancer genetics training outcomes for community-based clinicians","volume":"27","author":"Blazer","year":"2012","journal-title":"J Cancer Educ"},{"issue":"Suppl","key":"R121-20260729","first-page":"61S","article-title":"Results from MAGENTA: a national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk [abstract]","volume":"38","author":"Swisher","year":"2020","journal-title":"J Clin Oncol"},{"key":"R122-20260729","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R123-20260729","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R124-20260729","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R125-20260729","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.35480","article-title":"Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening","volume":"130","author":"Perez","year":"2024","journal-title":"Cancer"},{"key":"R126-20260729","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ajog.2024.09.100","article-title":"Pregnancy: an underutilized window of opportunity for genetic cancer risk assessment","volume":"232","author":"Grant","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R127-20260729","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/AOG.0000000000001951","article-title":"Carrier screening in the age of genomic medicine. Committee Opinion No. 690. American College of Obstetricians & Gynecologists","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R128-20260729","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10689-026-00536-5","article-title":"Misinterpreting the results: patient misconceptions about genetic cancer risk after obstetrical carrier screening","volume":"25","author":"Raghunandan","year":"2026","journal-title":"Fam Cancer"},{"key":"R129-20260729","doi-asserted-by":"crossref","first-page":"330.e1","DOI":"10.1016\/j.ajog.2024.04.014","article-title":"Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention","volume":"231","author":"Dioun","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"R130-20260729","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1038\/s41591-025-03986-z","article-title":"Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study","volume":"31","author":"Lunke","year":"2025","journal-title":"Nat Med"},{"key":"R131-20260729","doi-asserted-by":"crossref","first-page":"e2538198","DOI":"10.1001\/jamanetworkopen.2025.38198","article-title":"A genomic sequencing approach to newborn mass screening and its opportunities","volume":"8","author":"Carli","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:00:23Z","timestamp":1785348023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006304"}},"subtitle":["Overview of Gene-Specific Risks and Challenges in Genetics Care Delivery"],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":126,"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006304","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"2025-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}